Clinical Trials

LymphoidMyeloidOther hematologic neoplasmPlasma cell

15 enrolled

Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT00030875 2023-08-04

Bortezomib in Treating Patients With Mantle Cell Lymphoma

30 enrolled

Lymphoma, Lymphoma, Mantle-Cell

NCT00377052 2023-08-04

Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma

29 enrolled

Lymphoma, Lymphoma, Mantle-Cell

NCT01216683 2023-06-29

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

289 enrolled 34 charts

Lymphoma, Lymphoma, Follicular

NCT00114738 2022-10-10

EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma

53 enrolled 15 charts

Lymphoma, Lymphoma, Mantle-Cell

NCT02356458 2022-03-11

Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma

Phase 1/2 Terminated

58 enrolled

Lymphoma, Neoplasms, Recurrence, Lymphoma, Mantle-Cell

NCT00479167 2021-11-04

A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma

Phase 2 Terminated

1 enrolled 1 chart

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT01046006 2021-04-30

Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia

59 enrolled

Lymphoma, Waldenstrom Macroglobulinemia

NCT00598169 2020-08-10

Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma

23 enrolled

Lymphoma

NCT00182637 2020-08-03

Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma

5 enrolled 4 charts

DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00093704 2020-07-31

Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma

Phase 1 Terminated

1 enrolled

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Lymphoproliferative Disorders

NCT00980395 2019-12-30

VCR

24 enrolled 11 charts

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00439556 2019-09-10

Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant

40 enrolled 11 charts

Lymphoma, Hematologic Neoplasms

NCT00372905 2019-09-04

Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma

Phase 1/2 Terminated

18 enrolled 10 charts

DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular

NCT00290706 2019-05-28

A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma

Phase 1/2 Terminated

32 enrolled 12 charts

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Sezary Syndrome, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01164709 2019-05-15

Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer

DermatologicLymphoidOther hematologic neoplasmPlasma cell

18 enrolled

Congenital Abnormalities, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, Follicular, Multiple Myeloma, Mycosis Fungoides, Sezary Syndrome, Leukemia, Prolymphocytic, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Lymphoma, Extranodal NK-T-Cell

NCT00295932 2018-11-20

Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Phase 1/2 Completed

79 enrolled 19 charts

Leukemia, Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01848132 2018-09-19

Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.

121 enrolled

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT00963274 2018-04-23

Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

18 enrolled

Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Extranodal NK-T-Cell

NCT00772668 2017-12-11

Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL

Phase NA Terminated

3 enrolled 6 charts

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT00376961 2017-11-06

S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

68 enrolled 9 charts

Lymphoma, Lymphoma, Mantle-Cell

NCT01439750 2017-08-07

Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)

Phase 1 Unknown

13 enrolled

Lymphoma, Lymphoma, Mantle-Cell

NCT01132911 2017-07-02

A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas

CNSGenitourinaryLymphoidSarcoma

5 enrolled

Lymphoma, Neoplasms, Wilms Tumor, Neuroblastoma, Sarcoma

NCT01323920 2017-05-30

Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors

LymphoidMyeloidOther hematologic neoplasm

35 enrolled 9 charts

Leukemia, Lymphoma, Myelodysplastic Syndromes

NCT01171092 2017-01-11

A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma

Phase EARLY_PHASE1 Completed

21 enrolled

LymphoidPlasma cell

Lymphoma, Neoplasms, Plasma Cell

NCT00334438 2016-12-23

Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma

12 enrolled

Lymphoma, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT00634179 2016-10-27

A Phase I/II Trial of VR-CHOP in Lymphoma Patients

Phase 1/2 Completed

37 enrolled 7 charts

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell

NCT01029730 2016-08-19

Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

55 enrolled 7 charts

Lymphoma, Lymphoma, Non-Hodgkin

NCT00262860 2016-05-09

Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

18 enrolled 8 charts

Hodgkin Disease, Lymphoma

NCT00740415 2016-03-16

ManteauRiBVD

39 enrolled

DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Mantle-Cell

NCT00671112 2015-10-28

Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma

Phase 1 Terminated

30 enrolled

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Enteropathy-Associated T-Cell Lymphoma

NCT00958256 2015-04-13

Study of Bortezomib in Combination With Cyclophosphamide and Rituximab

22 enrolled 3 charts

Lymphoma, Lymphoma, Mantle-Cell

NCT00426855 2015-04-03

Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)

Phase 1/2 Completed

12 enrolled 6 charts

Lymphoma, Lymphoma, Non-Hodgkin

NCT00723658 2015-03-06

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

Phase 2 Withdrawn

Lymphoma, Waldenstrom Macroglobulinemia

NCT01386398 2015-01-21

Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma

Phase 3 Withdrawn

DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00513955 2014-11-05

Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

50 enrolled

Lymphoma, Lymphoma, Mantle-Cell

NCT01504776 2014-09-19

BUS48T

3 enrolled

Lymphoma, Lymphoma, Mantle-Cell

NCT00851552 2014-07-21

Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment

Phase 2 Terminated

9 enrolled 5 charts

Lymphoma, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

NCT00791011 2014-03-05

Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat

33 enrolled

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT00217503 2013-06-20

Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma

15 enrolled

Lymphoma

NCT00006098 2013-06-18

PS-341 in Treating Patients With Hematologic Cancer